Welcome Guest!  Login | Register | Help
Home News Screener Maps Groups Portfolio Insider Futures Forex Collaborate Store Elite
Settings
MNOV [NASD]
MediciNova Inc.
Index- P/E- EPS (ttm)-0.12 Insider Own0.10% Shs Outstand24.13M Perf Week-14.38%
Market Cap96.28M Forward P/E- EPS next Y- Insider Trans3.62% Shs Float20.38M Perf Month50.57%
Income-3.30M PEG- EPS next Q- Inst Own9.00% Short Float0.68% Perf Quarter103.57%
Sales6.00M P/S16.05 EPS this Y71.20% Inst Trans-0.14% Short Ratio1.02 Perf Half Y104.62%
Book/sh1.03 P/B3.87 EPS next Y- ROA-11.30% Target Price6.00 Perf Year54.65%
Cash/sh0.56 P/C7.13 EPS next 5Y20.00% ROE-13.40% 52W Range1.66 - 5.25 Perf YTD86.45%
Dividend- P/FCF- EPS past 5Y36.40% ROI-15.70% 52W High-24.00% Beta0.67
Dividend %- Quick Ratio13.10 Sales past 5Y- Gross Margin- 52W Low140.36% ATR0.37
Employees11 Current Ratio13.10 Sales Q/Q- Oper. Margin-55.00% RSI (14)59.94 Volatility14.35% 9.49%
OptionableNo Debt/Eq0.00 EPS Q/Q35.70% Profit Margin-55.00% Rel Volume0.90 Prev Close3.68
ShortableYes LT Debt/Eq0.00 EarningsAug 15 Payout- Avg Volume135.57K Price3.99
Recom1.00 SMA2012.74% SMA5036.95% SMA20075.16% Volume120,600 Change8.42%
04-Jan-13Reiterated Ladenburg Thalmann Buy $10.50 → $6
24-May-12Downgrade MLV & Co Buy → Hold
18-Oct-11Reiterated MLV Capital Buy $13 → $6
22-Jun-11Initiated Global Hunter Securities Buy $4
12-May-10Initiated Wedbush Outperform $13
12-Nov-08Reiterated Ladenburg Thalmann Buy $22 → $6
15-May-08Initiated Rodman & Renshaw Mkt Outperform $9
09-Jul-07Initiated Punk, Ziegel & Co Buy $22
23-Oct-14 07:00PM  U.S. Centers for Disease Control and Prevention (CDC) Supports Recruitment for MediciNova's Clinical Trial of MN-166 (Ibudilast) in ALS GlobeNewswire +8.42%
22-Oct-14 07:00PM  MediciNova Announces FDA Granted Orphan Drug Designation to MN-001 (tipelukast) for Idiopathic Pulmonary Fibrosis (IPF) GlobeNewswire
17-Oct-14 04:00PM  MEDICINOVA INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits EDGAR Online -10.73%
08-Oct-14 07:00PM  MediciNova Receives Feedback From FDA Regarding Study Protocol for Phase 2 Trial of MN-001 (tipelukast) in NASH GlobeNewswire +10.91%
06-Oct-14 07:00PM  MediciNova's MN-001 (tipelukast) NASH Abstract Selected for Late-Breaking Session at the 65th Annual AASLD Meeting in Boston GlobeNewswire +12.67%
29-Sep-14 07:00PM  Overview of MediciNova's Clinical Trial of MN-166 (ibudilast) in ALS to be Presented at The 13th Annual NEALS Meeting GlobeNewswire
23-Sep-14 07:00PM  MediciNova Provides Update on Phase 2b Trial of MN-166 (ibudilast) in Progressive MS GlobeNewswire
07-Sep-14 07:00PM  MediciNova Announces New NIDA Grant for MN-166 (ibudilast) in Opioid Dependence GlobeNewswire
01-Sep-14 07:00PM  MediciNova to Present Data on MN-001 (tipelukast) for the Treatment of Idiopathic Pulmonary Fibrosis (IPF) During the 18th International Colloquium on Lung and Airway Fibrosis (ICLAF) GlobeNewswire
28-Aug-14 04:00PM  MediciNova Rises on FDA's Nod on MN-166 Study Initiation Zacks
25-Aug-14 07:00PM  MediciNova to Initiate Clinical Trial of MN-166 (ibudilast) in ALS GlobeNewswire
22-Aug-14 01:04PM  MEDICINOVA INC Financials EDGAR Online Financials
19-Aug-14 06:01AM  MEDICINOVA INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits EDGAR Online +5.56%
18-Aug-14 07:00PM  MediciNova Announces Positive Interim Results of Phase 2a Study of MN-166 (ibudilast) in Opioid Dependence GlobeNewswire
14-Aug-14 09:00AM  MEDICINOVA INC Files SEC form 8-K, Regulation FD Disclosure EDGAR Online
13-Aug-14 05:00PM  MEDICINOVA INC Files SEC form 10-Q, Quarterly Report EDGAR Online
11-Aug-14 07:00PM  MediciNova Receives Notice of Allowance for New Patent Covering MN-001 and MN-002 for the Treatment of Nonalcoholic Fatty Liver Disease GlobeNewswire
05-Aug-14 07:30AM  MediciNova Announces Positive Results of MN-001 in Advanced NASH Mouse Model; MediciNova Requests a Meeting With FDA GlobeNewswire
11-Jul-14 05:15PM  MEDICINOVA INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial Statements and EDGAR Online
07-Jul-14 07:00PM  MediciNova to Present Data on MN-001 for the Treatment of NASH (Nonalcoholic Steatohepatitis) During the JDDW 2014 (Japan Digestive Disease Week 2014) GlobeNewswire
17-Jun-14 05:29PM  MEDICINOVA INC Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters to a Vote of Secu EDGAR Online
11-Jun-14 07:00PM  MediciNova Announces Positive Results in Study of MN-001 in Mouse Model of Pulmonary Fibrosis GlobeNewswire
09-May-14 10:33AM  MEDICINOVA INC Files SEC form 8-K, Regulation FD Disclosure EDGAR Online
08-May-14 05:05PM  MEDICINOVA INC Files SEC form 10-Q, Quarterly Report EDGAR Online
09-Apr-14 06:01AM  MEDICINOVA INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Change in Directors or Principal Offic EDGAR Online
08-Apr-14 07:00PM  MediciNova Appoints Yoshio Ishizaka to its Board of Directors GlobeNewswire +9.04%
07:00PM  MediciNova Announces Management Appointment GlobeNewswire
11:00AM  Treatments for Non-Alcoholic Steatohepatitis Making Clinical Strides Accesswire
28-Mar-14 06:07AM  MEDICINOVA INC Files SEC form 8-K, Regulation FD Disclosure EDGAR Online
27-Mar-14 05:04PM  MEDICINOVA INC Files SEC form 10-K, Annual Report EDGAR Online
10-Mar-14 09:00AM  MEDICINOVA INC Files SEC form 8-K, Other Events EDGAR Online
25-Feb-14 04:47PM  MediciNova: Gestation Is Slow And Uncomfortable - Birth Is Sudden And Unexpected at Seeking Alpha
17-Jan-14 03:52PM  Five Worst, Pandering Drug Stocks of J.P. Morgan Healthcare Confab Week at TheStreet
14-Jan-14 08:00AM  MediciNova Announces Positive Results in NASH Mouse Model With MN-001 and Prepares to Initiate Phase 2 Trial in the U.S. GlobeNewswire +32.09%
13-Jan-14 05:16PM  MEDICINOVA INC Files SEC form 8-K, Other Events EDGAR Online
30-Dec-13 06:10AM  MEDICINOVA INC Files SEC form 8-K, Change in Directors or Principal Officers EDGAR Online
13-Dec-13 06:07AM  MediciNova (MNOV) Jumps: Stock Adds 22.2% in Session Zacks -10.98%
13-Nov-13 06:02AM  MEDICINOVA INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Change in Directors or Principal Offic EDGAR Online
11-Nov-13 06:00PM  MediciNova Receives New Patent Covering MN-221 in Irritable Bowel Syndrome GlobeNewswire
08-Nov-13 06:19AM  MEDICINOVA INC Files SEC form 8-K, Regulation FD Disclosure EDGAR Online -6.11%
07-Nov-13 06:30PM  MediciNova Reports Third Quarter 2013 Results GlobeNewswire
05:17PM  MEDICINOVA INC Files SEC form 10-Q, Quarterly Report EDGAR Online
18-Oct-13 03:19PM  MEDICINOVA INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhibits EDGAR Online
16-Oct-13 05:00PM  MEDICINOVA INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Termination of a Material Definitive A EDGAR Online +5.04%
05:00PM  MediciNova Appoints Yutaka Kobayashi to Its Board of Directors GlobeNewswire
04:30PM  InPlay: MediciNova appoints Geoffrey O'Brien as Vice President Briefing.com
04:30PM  MediciNova Appoints Geoffrey O'Brien as Vice President GlobeNewswire
06-Oct-13 07:00PM  MediciNova Receives Notice of Allowance for New Patent Covering MN-029 (denibulin) di-hydrochloride GlobeNewswire
26-Sep-13 04:17PM  MEDICINOVA INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhibits EDGAR Online
25-Aug-13 07:00PM  National Institute on Alcohol Abuse and Alcoholism Funds New UCLA Clinical Trial of MediciNova's MN-166 in Treating Alcoholism GlobeNewswire
09-Aug-13 09:01AM  MEDICINOVA INC Files SEC form 8-K, Regulation FD Disclosure EDGAR Online
08-Aug-13 05:30PM  MediciNova Reports Second Quarter 2013 Results GlobeNewswire
05:11PM  MEDICINOVA INC Files SEC form 10-Q, Quarterly Report EDGAR Online
30-Jul-13 09:02AM  MEDICINOVA INC Files SEC form 8-K, Change in Directors or Principal Officers EDGAR Online
18-Jul-13 07:00PM  MediciNova Announces Initiation of a Cooperative Phase 2b Trial of MN-166 in Progressive Multiple Sclerosis GlobeNewswire
17-Jul-13 09:03AM  MEDICINOVA INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits EDGAR Online
20-Jun-13 06:48PM  Nasdaq stocks posting largest volume increases AP -11.87%
19-Jun-13 05:15PM  MediciNova Presents MN-166 Data Zacks +31.13%
18-Jun-13 06:00PM  UCLA Presents Data on MediciNova's MN-166 in Methamphetamine Addiction at the 75th Annual Meeting of the College on Problems of Drug Dependence GlobeNewswire
17-Jun-13 07:32AM  MEDICINOVA INC Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters to a Vote of Secu EDGAR Online
07-Jun-13 10:21AM  MEDICINOVA INC Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Tr EDGAR Online
13-May-13 01:34PM  Monday Sector Leaders: Biotechnology, Drugs at Forbes +16.48%
09-May-13 11:13PM  MEDICINOVA INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of Equity Securities EDGAR Online -26.78%
02:01AM  MEDICINOVA INC Files SEC form 8-K, Regulation FD Disclosure EDGAR Online
08-May-13 05:30PM  MediciNova Reports First Quarter 2013 Results GlobeNewswire +10.50%
10:10AM  MEDICINOVA INC Files SEC form 10-Q, Quarterly Report EDGAR Online
18-Apr-13 06:35AM  MedicNova enters into 6M equity distribution agreement with Macquarie at theflyonthewall.com +6.72%
17-Apr-13 11:19PM  MEDICINOVA INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exhibits EDGAR Online
09:08AM  MEDICINOVA INC Files SEC form 8-K, Other Events EDGAR Online
29-Mar-13 02:02AM  MEDICINOVA INC Files SEC form 8-K, Regulation FD Disclosure EDGAR Online
28-Mar-13 05:30PM  MediciNova Reports Fourth Quarter and Full Year 2012 Results GlobeNewswire
10:16AM  MEDICINOVA INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits EDGAR Online
10:08AM  MEDICINOVA INC Files SEC form 10-K, Annual Report EDGAR Online
MediciNova, Inc., a biopharmaceutical company, focuses on acquiring and developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs for the United States market. Its product candidates include MN-166, a anti-inflammatory and neuroprotective agent, which has completed Phase 2 clinical trials for the treatment of neurological disorders; MN-221, a 2-adrenergic receptor agonist that has completed Phase 2b clinical trails for the treatment of acute exacerbations of asthma; MN-001, an orally bioavailable small molecule compound, which has completed Phase 2 clinical trials for the treatment of nonalcoholic steatohepatitis; and MN-029, a novel tubulin binding agent under development for the treatment of solid tumors. MediciNova, Inc. was founded in 2000 and is based in La Jolla, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Kobayashi YutakaDirectorSep 11Buy2.9510,00029,50025,000Sep 11 05:44 PM
Kobayashi YutakaDirectorSep 03Buy2.6615,00039,84915,000Sep 04 06:50 PM